...
首页> 外文期刊>Bioconjugate Chemistry >In Vivo Pretargeting Based on Cysteine-Selective Antibody Modification with IEDDA Bioorthogonal Handles for Click Chemistry
【24h】

In Vivo Pretargeting Based on Cysteine-Selective Antibody Modification with IEDDA Bioorthogonal Handles for Click Chemistry

机译:基于半胱氨酸选择性抗体改性的体内预靶向与IEDDA生物正交手柄进行单击化学

获取原文
获取原文并翻译 | 示例

摘要

Pretargeted imaging has emerged as an effective multistep strategy aiming to improve imaging contrast and reduce patient radiation exposure through decoupling of the radioactivity from the targeting vector. The inverse electron-demand Diels–Alder (IEDDA) reaction between a trans -cyclooctene (TCO)-conjugated antibody and a labeled tetrazine holds great promise for pretargeted imaging applications due to its bioorthogonality, rapid kinetics under mild conditions, and formation of stable products. Herein, we describe the use of functionalized carbonylacrylic reagents for site-specific incorporation of TCO onto a human epidermal growth factor receptor 2 (HER2) antibody (THIOMAB) containing an engineered unpaired cysteine residue, generating homogeneous conjugates. Precise labeling of THIOMAB–TCO with a fluorescent or radiolabeled tetrazine revealed the potential of the TCO-functionalized antibody for imaging the HER2 after pretargeting in a cellular context in a HER2 positive breast cancer cell line. Control studies with MDA–MD-231 cells, which do not express HER2, further confirmed the target specificity of the modified antibody. THIOMAB–TCO was also evaluated in vivo after pretargeting and subsequent administration of an ~(111)In-labeled tetrazine. Biodistribution studies in breast cancer tumor-bearing mice showed a significant activity accumulation on HER2~(+) tumors, which was 2.6-fold higher than in HER2~(–) tumors. Additionally, biodistribution studies with THIOMAB without the TCO handle also resulted in a decreased uptake of ~(111)In–DOTA–Tz on HER2~(+) tumors. Altogether, these results clearly indicate the occurrence of the click reaction at the tumor site, i.e., pretargeting of SK-BR-3 HER2-expressing cells with THIOMAB–TCO and reaction through the TCO moiety present in the antibody. The combined advantages of site-selectivity and stability of TCO tagged-antibodies could allow application of biorthogonal chemistry strategies for pretargeting imaging with minimal side-reactions and background.
机译:预注塑成像被出现为旨在改善成像对比度并通过从靶向载体的放射性去耦降低患者辐射暴露的有效多步策略。由于其生物正性,在温和条件下的生物正性,快速动力学,以及在温和条件下的快速动力学,以及在温和条件下的快速动力学,以及在温和条件下的快速动力学,并且在温和的条件下,逆电子(IEDDA)反应是逆的电子需求Diels - 桤木(IEDDA)反应对预注射的成像应用产生了巨大的承诺稳定的产品。在此,我们描述了使用官能化羰基丙烯酸试剂用于将TCO的位点特异性掺入到人表皮生长因子受体2(HER2)抗体(ThioMab)上,含有工程化的未配对半胱氨酸残基,产生均匀的缀合物。将ThioMab-TCO与荧光或放射性标记的四嗪的精确标记显示TCO官能化抗体的电位,用于在HER2阳性乳腺癌细胞系中的细胞背景下进行预靶向HER2。使用不表达HER2的MDA-MD-231细胞的对照研究进一步证实了改性抗体的靶特异性。在预靶向和随后施用标记的四嗪后,还在体内评估ThioMab-TCO。乳腺癌肿瘤瘤小鼠的生物分布研究表明HER2〜(+)肿瘤上的显着活动积累,比在HER2〜( - )肿瘤高2.6倍。另外,没有TCO手柄的硫米布的生物分布研究也导致HER2〜(+)肿瘤上的〜(111)in-DOTA-TZ的摄取降低。总的来说,这些结果清楚地表明肿瘤部位的点击反应的发生,即用硫聚物-TCO与抗体中存在的TCO部分反应的SK-BR-3 Her2表达细胞的咔哒反应。 TCO标记 - 抗体的场地选择性和稳定性的组合优势可以允许在最小的副反应和背景中施加预靶向成像的生物正交化策略。

著录项

  • 来源
    《Bioconjugate Chemistry 》 |2021年第1期| 共12页
  • 作者单位

    Center for Nuclear Sciences and Technologies (CTN) Instituto Superior Técnico Universidade de Lisboa;

    Instituto de Medicina Molecular Jo?o Lobo Antunes (iMM-JLA) Faculdade de Medicina Universidade de Lisboa Avenida Professor Egas Moniz;

    Center for Nuclear Sciences and Technologies (CTN) Instituto Superior Técnico Universidade de Lisboa;

    Biosystems and Integrative Sciences Institute (BioISI) Faculdade de Ciências Universidade de Lisboa;

    Center for Nuclear Sciences and Technologies (CTN) Instituto Superior Técnico Universidade de Lisboa;

    Center for Nuclear Sciences and Technologies (CTN) Instituto Superior Técnico Universidade de Lisboa;

    Instituto de Medicina Molecular Jo?o Lobo Antunes (iMM-JLA) Faculdade de Medicina Universidade de Lisboa Avenida Professor Egas Moniz;

    Center for Nuclear Sciences and Technologies (CTN) Instituto Superior Técnico Universidade de Lisboa;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 生物化学 ;
  • 关键词

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号